Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.
A bankruptcy court in Texas rejected J&J’s proposed bankruptcy plan to settle claims related to its talc lawsuits for the ...
Zacks Investment Research on MSN5h
Pharma Stock Roundup: FDA Nod to SNY, AZN & NVS, JNJ Talc Suits FailureThis week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback